The stock is coming off a strong year.
In addition to the reversion trade factors, the sector has benefited from the steady move down in interest rates in 2025. This has been a tailwind for higher beta areas of the small caps, like small ...
Hosted on MSN
Inside the Recent Strength in Biotech ETFs
Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied about 35% over the past six months (as of Nov. 20, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 12%). Year to ...
SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial ...
Biotech-based exchange-traded fund (“ETF”) iShares Biotechnology ETF IBB rallied 30.2% over the past six months (as of Oct. 15, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 26.5%). Year to date ...
Scenic Biotech is advancing modifier therapy, a radical new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance ...
The following medical device manufacturer and biotech mergers occurred in the past two months. 1. In two days, Minneapolis-based Medtronic announced two acquisition deals. In the first deal, Medtronic ...
Exceeded 10,000 patients treated to date with CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) Increased CARVYKTI ® manufacturing capacity with the physical expansion of the Raritan facility, now the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results